Severe gastrointestinal toxicity of MEK inhibitors
Gastrointestinal toxicities of MEK inhibitors in melanoma patients are frequent. In clinical trials, the most common digestive adverse events were nausea, vomiting, and diarrhoea. However, severe toxicities such as colitis and gastrointestinal perforation, some with fatal outcomes, have been reported. These rare but severe adverse events are not well described. We performed a retrospective analysis of all patients with stage IV and unresectable stage III melanoma treated with a MEK inhibitors at Saint-Louis Hospital, Paris, between 1 August 2013 and 15 October 2018. Among 119 patients exposed to MEK inhibitors, 78 were tre...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Short Communications: Clinical Research Source Type: research

Are patients in haemodialysis good candidates for immunotherapy treatment?
The effectiveness and safety of nivolumab, an anti-programmed cell death protein 1 mAbmonoclonal antibody, in patients with renal replacement therapy is unclear, with limited evidence supporting its usefulness in this context. Therefore, we report a case of recurrent metastatic melanoma in a patient on haemodialysis successfully treated with nivolumab. As seen in patients without renal impairment, significant regression of the lesions was observed after 8 weeks of treatment, reaching complete clinical response after 4 months. During follow-up, no dose adjustment, delay, or treatment suspension due to toxicity were required...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Short Communications: Clinical Research Source Type: research

Immune-related pancreatitis associated with checkpoint blockade in melanoma
We present a patient who developed an immune-related pancreatitis within the first 4 months of immunotherapy. Treatment with high dose systemic glucocorticosteroids with very slow tapering over a total period of 6.5 months was necessary to keep the patient symptom free as well as to maintain long-term normalization of serum lipase. Checkpoint blockade related pancreatitis may occur as acute or chronic disease and may lack any radiographic signs. As in our case, very slow tapering of initially high dose systemic glucocorticosteroids seems to be a crucial requirement for lasting recovery. Even after successful treatment, lat...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Short Communications: Clinical Research Source Type: research

Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status
Tumor heterogeneity affects the efficacy of anticancer treatment as tumor subclones with distinct molecular patterns may be present within one tumor, leading to differing sensitivities to chemotherapeutic agents. In the present study, six melanoma tissue fragments were obtained from different parts of tumor of four patients and then the effect of vemurafenib treatment on biological characteristics and molecular processes of cell cultures was estimated by using MTT-test, apoptosis, migration and invasion assays, PCR real time. There was different BRAF status determined between cells derived from the central and peripheral r...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Short Communications: Basic Science Source Type: research

Protein kinase C-α is upregulated by IMP1 in melanoma and is linked to poor survival
The oncofetal mRNA-binding protein, IMP1 or insulin-like growth factor-2 mRNA-binding protein 1 (IGF2BP1), promotes the overexpression of several oncogenic proteins by binding to and stabilizing their mRNAs. IMP1 is frequently overexpressed in melanoma and is associated with a poor prognosis, but the full spectrum of IMP1 target transcripts remains unknown. Here, we report the identification of protein kinase C-α (PKCα), as a novel molecular target of IMP1. Overexpression of IMP1 resulted in increased levels of PKCα, while RNAi knockdown of IMP1 resulted in decreased PKCα mRNA stability, PKCα ...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Short Communications: Basic Science Source Type: research

Disseminated intravascular coagulation and melanoma: a novel case occurring in metastatic melanoma with: BRAF: and: NRAS: mutations and systematic review
Disseminated intravascular coagulation is a complex and potentially lethal complication of malignancy, in which the fundamental abnormality is excessive activation of the coagulation system. It is a rare complication of melanoma which can be difficult to diagnose in some circumstances, leading to delay in treatment. Herein, we describe the first case of disseminated intravascular coagulation occurring in BRAF and NRAS-mutant metastatic melanoma, and systematically review the literature regarding disseminated intravascular coagulation in melanoma. This review summarizes the reported cases of disseminated intravascular coagu...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program
Given the approval of dabrafenib in patients with BRAF-mutant metastatic melanoma, a better understanding of treatment patterns and clinical outcomes with dabrafenib in a clinical setting is warranted. We performed a retrospective chart review of patients who received dabrafenib in a compassionate use setting through the Named Patient Program (DESCRIBE I study) during December 2010–August 2013 in Europe, New Zealand and Australia. Of the 331 Named Patient Program patients included, the majority (95.8%) had stage IV disease at dabrafenib initiation and 39.9% had brain metastases (BMs). Dabrafenib was used first line i...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research

Inflammatory side effects of BRAF and MEK inhibitors
The aim of this study was to describe inflammatory side effects in patients treated with BRAF and MEK inhibitors at a single tertiary care institution. This was a retrospective chart review of patients prescribed single-agent or combination BRAF and MEK inhibitors from January 2010 until May 2015. The primary outcome was the presence of inflammatory side effects. Among 124 patients, 56.4% were male, the median age was 59 years, and most (91.1%) were treated for metastatic melanoma. Most patients (74.2%) developed inflammatory side effects, some with multiple occurrences, for a total of 211 occurrences. The overall prevalen...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research

Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases
The common adverse effects of immune checkpoint blockade therapy are well recognised. However, neurological adverse effects of checkpoint inhibitor therapy are less widely appreciated, and their clinical management remains challenging. Therefore, we report our experience of managing acute, life-threatening neurological toxicity during immune checkpoint inhibitor therapy. Five male patients with stage IV melanoma underwent anti-programmed cell death protein 1 therapy (monotherapy or combination therapy with anti-cytotoxic T-lymphocyte antigen-4 antibodies) and developed severe neurological symptoms and signs including heada...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research

Prognostic role of disease extent and lymphocyte–monocyte ratio in advanced melanoma
In conclusion, LMR seems to be associated with OS. Further prospective investigations are needed to confirm these data and introduce peripheral blood cell count in daily clinical use. (Source: Melanoma Research)
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research

Prognostic significance of CD163 expression and its correlation with cyclooxygenase-2 and vascular endothelial growth factor expression in cutaneous melanoma
In several cancers, tumor progression is associated with the infiltration of tumor-associated macrophages (TAMs). The aim was to evaluate the prognostic significance of expression of CD163 and CD68 (TAMs’ markers) and their correlation with vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) expression in cutaneous melanoma. Diagnostic tissues from 102 patients of cutaneous melanoma were evaluated by immunohistochemistry for their CD68, CD163, VEGF, and COX-2 expression. Correlations between the proteins were then investigated. Clinicopathological features, overall survival (OS), and progression-fr...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research

Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy
Neuroblastoma RAS viral oncogene homolog is a commonly mutated oncogene in melanoma, and therapeutic targeting of neuroblastoma RAS viral oncogene homolog has proven difficult. We characterized the expression and phenotypic functions of five recently discovered splice isoforms of neuroblastoma RAS viral oncogene homolog in melanoma. Canonical neuroblastoma RAS viral oncogene homolog (isoform-1) was expressed to the highest degree and its expression was significantly increased in melanoma metastases compared to primary lesions. Isoform-5 expression in metastases showed a significant, positive correlation with survival and t...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Translational Research Source Type: research

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma
Germline mutations of BRCA1 and BRCA2 predispose individuals to a high risk of breast and ovarian cancer, and elevated risk of other cancers, including those of the pancreas and prostate. BRCA2 mutation carriers may have increased risk of uveal melanoma (UM) and cutaneous melanoma (CM), but associations with these cancers in BRCA1 mutation carriers have been mixed. Here, we further assessed whether UM and CM are associated with BRCA1 or BRCA2 by assessing the presence, segregation and reported/predicted pathogenicity of rare germline mutations (variant allele frequency (Source: Melanoma Research)
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Translational Research Source Type: research

Nuclear morphometric analysis in tissue as an objective tool with potential use to improve melanoma staging
Alterations in nuclear size and shape are commonly observed in cancers, and its objective evaluation may provide valuable clinical information about the outcome of the disease. Here, we applied the nuclear morphometric analysis in tissues in hematoxylin and eosin-digitized slides of nevi and melanoma, to objectively contribute to the prognostic evaluation of these tumors. To this, we analyzed the nuclear morphometry of 34 melanomas classified according to the TNM stage. Eight cases of melanocytic nevi were used as non-neoplastic tissues to set the non-neoplastic parameters of nuclear morphology. Our samples were set as G1 ...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Translational Research Source Type: research

Global microRNA profiling of metastatic conjunctival melanoma
This study aimed to investigate the microRNA (miRNA) profile in primary tumors from conjunctival melanoma with and without subsequent metastatic spread along with their coupled distant metastases to identify miRNAs likely to be involved in metastatic progression. This observational study included 13 patients with metastatic conjunctival melanoma (follow-up: 1–39 years) treated at a Danish referral center. Twenty-five patients with nonmetastatic conjunctival melanoma (follow-up: 5–17 years) were included for comparison. Global miRNA profiling was performed with the Affymetrix GeneChip 4.1 microarray. Taqman qPCR...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Original Articles: Basic Science Source Type: research

Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review
Immune checkpoint inhibitors (ICIs), which target CTLA-4 or PD-(L)1 molecules, have shown impressive therapeutic results. Durable responses, however, are only observed in a segment of the patient population and must be offset against severe off-target immune toxicity and high costs. This calls for biomarkers that predict response during ICI treatment. Although many candidate biomarkers exist, as yet, there has been no systematic overview of biomarkers predictive during. Here, we provide a systematic review of the current literature of ICI treatment to establish an overview of candidate predictive biomarkers during ICI trea...
Source: Melanoma Research - September 3, 2019 Category: Cancer & Oncology Tags: Review Article Source Type: research

Dusky erythema secondary to anti-MEK therapy
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research

Exacerbation of skin psoriasis when associating an MEK inhibitor with anti-PD1 immunotherapy for metastatic melanoma
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research

Partial response of metastatic melanoma to BRAF-inhibitor-monotherapy in a pregnant patient with no fetal toxicity
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research

IRF4 rs12203592*T/T genotype is associated with nodular melanoma
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research

Refined common terminology criteria for adverse events criteria – respective systemic melanoma therapy
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research

Two cases of pneumonitis induced by targeted therapy
We report two cases of cobimetinib-induced and vemurafenib-induced reversible interstitial pneumonitis. Two patients presenting a BRAF-mutated metastatic melanoma were treated with cobimetinib and vemurafenib. After 3 months, they developed severe feverish dyspnea. Thoracic imaging showed a pattern of organizing pneumonia in one case and a pattern of hypersensitivity pneumonitis in the other case. Infectious and cardiogenic causes were eliminated. An improvement was noted after discontinuation of cobimetinib, vemurafenib, and introducing steroids. Treatment was switched to dabrafenib (a BRAF inhibitor) with no recurrence o...
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Short Communications Source Type: research

Acute progressive neuropathy–myositis–myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma
Targeting immune cells instead of cancer cells is a new and successful therapeutic approach in patients with a variety of advanced cancers. Blocking antibodies bind to specific immune-checkpoint molecules namely cytotoxic T-lymphocyte-associated antigen 4, programmed cell death protein-1, and programmed cell death-ligand 1. However, their mechanism of action can lead to immune-related adverse events. In particular, neurological immune-related adverse events present, currently, a problem, as they are rare, difficult to diagnose, and are often high grade or even fatal. Here, we describe four cases with metastatic melanoma wh...
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Short Communications Source Type: research

Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors
This retrospective cohort study assessed the prognostic significance of distant metastasis-free interval (DMFI) in patients with relapsed BRAF-mutant melanoma treated with BRAF with or without MEK inhibitors (BRAFi ± MEKi). Patients with a DMFI of up to 24 months were compared with those with DMFI of more than 24 months, with regard to their postrelapse progression-free survival (PR-PFS) and overall survival (PR-OS). In total, 109 patients were included in the study. Median DMFI was 25.3 (range: 3.4–188.2) months. Median PR-PFS in patients with DMFI of more than 24 months was 7.9 months [95% confidence interva...
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Original Articles Source Type: research

A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1
A vaccine that could expand melanoma-specific T cells might reduce the risk of recurrence of resected melanoma and could provide an alternative or adjunct to standard immunotherapy options. We tested the safety and immunogenicity of a vaccine coupling a melanoma-associated peptide with a xenogenic peptide (to promote epitope spreading) and/or resiquimod (to activate antigen-presenting cells). HLA-A2-positive patients with resected stage II, III, and IV melanoma were assigned to treatment on one of three schedules. All patients received three subcutaneous doses of the peptide MART-1a mixed with Montanide. In addition, patie...
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Original Articles Source Type: research

Comparing survival outcomes in early stage desmoplastic melanoma with or without adjuvant radiation
Desmoplastic melanoma (DM) due to its rare and locally aggressive nature, can be difficult to study and to treat effectively. Whether the optimal treatment approach for these tumors should include adjuvant radiation has been unclear in the literature. In this retrospective study of the National Cancer Database, 2390 patients with localized DM were included for analysis. 2082 were treated with wide local excision (WLE) and 308 were treated with wide local excision and adjuvant radiation therapy (WLE + RT). Overall survival (OS) in these groups was compared on crude and adjusted analyses utilizing Cox proportional hazards re...
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Original Articles Source Type: research

Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity
The objective was to determine if the absence of FasL signaling would affect melanoma liver metastases by influencing the antimelanoma properties of liver natural killer (NK) cells. Melanoma liver metastases were induced in wild-type C57BL/6 mice and the gld/gld mutant C57BL/6 mouse strain that expresses a defective form of FasL (CD95L) that fails to engage and signal via the Fas receptor (CD95). Liver metastases were produced by intrasplenic injection of B16LS9 melanoma cells. Liver NK cell activity directed against murine B16LS9 melanoma cells was determined in a 24 h in-vitro cytotoxicity assay. Liver NK cells, NK T cel...
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Original Articles Source Type: research

Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells
Selective inhibition of the mutant BRAF protein is a highly promising therapeutic approach for melanoma patients carrying the BRAFV600E mutation. Despite the remarkable clinical response, most patients develop resistance and experience tumour regrowth. To clarify the molecular background of BRAF inhibitor resistance, we generated four drug-resistant melanoma cell lines from paired primary/metastatic cell lines using a vemurafenib analogue PLX4720. Three of the resistant cell lines showed decreased proliferation after drug withdrawal, but the proliferation of one cell line (WM278RES) increased notably. Furthermore, we obser...
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Original Articles Source Type: research

RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2
The development of immunotherapy has improved the treatment of melanoma; however, resistance and frequent recurrence persist and remain a major problem. N6-methyladenosine (m6A) is the most abundant epitranscriptomic mark on mRNA and is essential for various physiological processes; however, its role in melanoma is unknown. Utilizing human normal melanocyte and melanoma cell lines, we analyzed the expression of METTL3 by quantitative RT-PCR. We inhibited the METTL3 expression by shRNA and analyzed the effects on melanoma cell proliferation, colony formation ability, and invasion. Finally, we assessed the role of METTL3 by ...
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Original Articles Source Type: research

Decreased expression of nemo-like kinase in melanoma is correlated with increased vascularity and metastasis
This study aimed to investigate whether NLK expression in melanoma correlates with VEGFR2-related angiogenesis and melanoma metastasis. Immunohistochemistry analysis using 175 biopsied tissues of melanoma patients showed that NLK is expressed in 73.7% of melanoma tissues, whereas 26.3% of the samples showed absent expression of NLK. In metastatic melanoma, the expression of NLK was significantly lower than that in primary melanoma (P = 0.002). Furthermore, tissues with a lower expression of NLK showed a higher microvessel density as detected by VEGFR2 expression compared with tissues showing higher NLK expression. These da...
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Original Articles Source Type: research

Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain
Chondroitin sulfate proteoglycan 4 (CSPG4) is a cell surface proteoglycan that enhances malignant potential in melanoma and several other tumor types. CSPG4 functions as a transmembrane scaffold in melanoma cells to activate oncogenic signaling pathways such as focal adhesion kinase (FAK) and extracellular signal regulated kinases 1,2, that control motility, invasion and anchorage independent growth. Here, we demonstrate that CSPG4 promotes directional motility and anchorage independent growth of melanoma cells by organizing and positioning a signaling complex containing activated FAK to lipid rafts within the plasma membr...
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Original Articles Source Type: research

Adjuvant systemic therapy in high-risk melanoma
In resected high-risk melanoma (stage IIB/C-III) the risk of locoregional and/or distant recurrence is substantial and so far adjuvant therapies have been fairly unsuccessful. Interferon showed slight improvements in recurrence-free survival (RFS) but failed to convincingly improve overall survival (OS). In these patients, adjuvant therapy with treatments that show promising results in stage IV disease is arising. Studies using immune checkpoint blockade with anti-CTLA-4 and anti-PD-1 agents reveal convincing RFS benefits. OS rates, however, are not mature yet in most studies. Only ipilimumab has shown an OS benefit but at...
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research

Expression of cancer/testis antigens in cutaneous melanoma: a systematic review
The cancer/testis antigen (CTA) family is a group of antigens whose expression is restricted to male germline cells of the testis and various malignancies. This expression pattern makes this group of antigens potential targets for immunotherapy. The aim of this study was to create an overview of CTA expressed by melanoma cells at mRNA and protein level. A systematic literature search was performed in Medline (PubMed) and Embase from inception up to and including February 2018. Studies were screened for eligibility by two independent reviewers. A total of 65 full-text articles were included in the final analysis. A total of...
Source: Melanoma Research - June 28, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research

TERT promoter mutation subtypes in 20 in-situ melanomas
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: LETTERS TO THE EDITOR Source Type: research

Eye immune privilege? Nivolumab plus ipilimumab: successful treatment in a patient with cutaneous melanoma and ocular metastases
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: LETTERS TO THE EDITOR Source Type: research

Melanoma Explorer: a web application to allow easy reanalysis of publicly available and clinically annotated melanoma omics data sets
Validating newly discovered biomarkers in large, publicly available data sets is often difficult and requires specialized computer programming skills. Melanoma Explorer is a web application that enables easy interrogation of melanoma omics data sets that are freely available in online data repositories with a point-and-click interface. Two use cases are demonstrated. First, the relationship of lysozyme mRNA expression is shown to be prognostic in two independent gene expression microarray data sets. Second, a figure from a journal article showing the relationship of tumour thickness and miR-382 abundance is reproduced. Mel...
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: SHORT COMMUNICATIONS Source Type: research

Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases
We report three cases of cutaneous lupus associated with pembrolizumab therapy for advanced melanoma. One patient had a previous diagnosis of histologically proven discoid lupus erythematosus, well-controlled without treatment for over 2 years, which flared on first exposure to pembrolizumab. The remaining two patients had no previous history of autoimmune disease; both developed cutaneous eruptions, histologically and immunohistologically, in keeping with subacute cutaneous lupus following treatment with pembrolizumab. Our report bolsters what is currently an exceedingly small body of evidence documenting the development ...
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: SHORT COMMUNICATIONS Source Type: research

Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature
We describe a unique case of conception and pregnancy, with successful maternal and foetal outcomes, in a patient with metastatic melanoma who had received combination anti-CTLA-4 and anti-PD1 therapy. A 32-year-old G0P0 lady, with a 10-year history of infertility of unclear cause, was found to be 7 weeks pregnant after 14 months of nivolumab maintenance therapy, having previously received combination ipilimumab and nivolumab. Nivolumab was ceased upon discovery of pregnancy in the first trimester. The patient had an uneventful pregnancy, followed by spontaneously premature labour, and delivered by caesarean section at 33 ...
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: SHORT COMMUNICATIONS Source Type: research

Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients
This study demonstrates that treatment with anti-PD-1 antibodies may impair glucose metabolism, as measured by increasing HbA1c levels. (Source: Melanoma Research)
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: SHORT COMMUNICATIONS Source Type: research

Multiple primary melanoma with the Meyerson phenomenon in a young patient
In conclusion, MP is not specific for benignity, even when multiple simultaneous lesions are affected. Inflammatory changes can make melanocytic lesions difficult to interpret, both on dermoscopic regression features and on histopathologic examination. Therefore, it is recommended to consider the complete excision of melanocytic lesions with atypical vessels and/or extensive regression phenomena more than 50%. Further studies are needed to know whether the presence of a melanoma could induce a remote immune response in other benign melanocytic lesions. (Source: Melanoma Research)
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: SHORT COMMUNICATIONS Source Type: research

Inositol hexaphosphate plus inositol induced complete remission in stage IV melanoma: a case report
We present a case report of a patient with metastatic melanoma who declined traditional therapy and opted to try over the counter supplement IP6+inositol instead. To our surprise, the patient achieved a complete remission and remains in remission 3 years later. On the basis of this case and previous preclinical studies, we believe further research is indicated in exploring antiproliferative and potential immune stimulating effects of IP6+inositol in patients with metastatic melanoma. (Source: Melanoma Research)
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: SHORT COMMUNICATIONS Source Type: research

Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma
The gut microbiota impacts response to immunotherapy in cancer patients. We sought to evaluate the role of physiologic colonic fluorine-18-fluorodeoxyglucose (18F-FDG) uptake, a test that was recently shown to reflect colonic bacterial load, as a possible predictor for response to immunotherapy. We carried out a retrospective study in metastatic melanoma patients who received the immune checkpoint inhibitor ipilimumab as first-line therapy. All patients underwent an 18F-FDG PET scan before treatment initiation. The primary outcome was defined as response to treatment according to the RECIST criteria. Regions of interest we...
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: SHORT COMMUNICATIONS Source Type: research

Eruptive cherry angiomas and skin melanoma: a fortuitous association?
The aim of the study was to assess the association between eruptive cherry angiomas (CAs) and malignant melanoma (MM). Secondary objectives included investigating (i) this association in different age subgroups, and (ii) the association of eruptive CAs with other variables such as malignant tumours, in general, and immunosuppressive treatments. This cross-sectional study involved all patients referred to the outpatient Dermatology-Oncology Units of the universities of Ferrara and Bologna, Italy, and submitted to total body skin examination. These patients were included in a previously collected series. We recorded age, sex...
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: SHORT COMMUNICATIONS Source Type: research

Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy
In conclusion, this case report suggests that a major regression of multiple nevi on ipilimumab might be associated with immunotherapy response. (Source: Melanoma Research)
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: SHORT COMMUNICATIONS Source Type: research

Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive
Patients with BRAF V600 (BRAF) mutated metastatic melanoma are eligible for therapy with both immune checkpoint inhibitors and targeted therapies, making treatment choice a complex decision. The present study aimed to describe patterns of treatment with immunotherapy and targeted therapy and BRAF testing in patients with metastatic melanoma presumed to have BRAF mutations (BRAF+) in the years following the approval of the newer generation of immune checkpoint inhibitors and targeted therapies (2014–2016). Two large US commercial claims databases [Truven Health Analytics MarketScan and IQVIA Real-World Data Adjudicate...
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: ORIGINAL ARTICLES: Epidemiology of melanoma Source Type: research

Regression rate of choroidal melanoma following iodine-125 brachytherapy is not associated with metastatic spread
Nearly half of choroidal melanomas progress to the metastatic stage at 15 years. The purpose of our study was to evaluate the prognostic value of tumour-height regression rate in medium-sized choroidal melanomas treated with iodine-125 brachytherapy. A retrospective cohort study was performed on 128 patients with medium-sized choroidal melanoma who were treated with iodine-125 brachytherapy. Tumour characteristics including tumour apical height at baseline and after irradiation, recurrence, metastasis and mortality were collected from patients’ records. Regression rate was defined in mm/month or in percentage of base...
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: ORIGINAL ARTICLES: Clinical research Source Type: research

Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience
Pembrolizumab is an anti-programmed cell death-1 monoclonal antibody, currently representing the first-line treatment for advanced melanoma. Apart from registration trials, there is a paucity of data on its effectiveness and safety in a real-world setting. We retrospectively analyzed patients with metastatic melanoma treated at our institution in the context of an Expanded Access Program. Survival outcomes were assessed using Kaplan–Meier and Cox hazard models. Overall, 42 melanoma patients were treated. BRAF status was wild type in 30 (71%) patients and mutated in 12 (29%). Twelve (29%) patients received pembrolizum...
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: ORIGINAL ARTICLES: Clinical research Source Type: research

Impact of initial stage on metastatic melanoma survival
Patients diagnosed with metastatic melanoma have varied clinical courses, even in patients with similar disease characteristics. We examine the impact of initial stage of melanoma diagnosis, BRAF status of primary melanoma, and receiving adjuvant therapy on postmetastatic overall survival (pmOS). We studied melanoma patients presenting to Perlmutter Cancer Center at New York University and prospectively enrolled in New York University melanoma biospecimen database and followed up on protocol-driven schedule. Patients were stratified by stage at initial melanoma diagnosis as per AJCC 7th ed. guidelines. pmOS was determined ...
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: ORIGINAL ARTICLES: Clinical research Source Type: research

Combination of ω-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study
The recently developed therapeutic strategies have led to unprecedented improvements in the control of metastatic melanoma and in the survival of specific subgroups of patients. However, drug resistance, low response rates, and undesired side effects make these treatments not suitable or tolerable for all the patients, and chemotherapeutic treatments appear still indispensable, at least for subgroups of patients. New combinatory strategies are also under investigation as tailored treatments or salvage therapies, including combined treatments of immunotherapy with conventional chemotherapy. On this basis, and in considerati...
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: ORIGINAL ARTICLES: Translational research Source Type: research

Prognostic role of NRAS isoforms in Chinese melanoma patients
We examined the expression levels of NRAS isoforms of 140 melanoma samples using quantitative real-time PCR. Furthermore, the relationship of mRNA expression of NRAS isoforms to clinicopathological characteristics and survival of patients was analyzed. Statistical analysis showed that NRAS isoform 2 expression was correlated with melanoma subtypes (P=0.007), and NRAS isoform 4 expression was correlated with tumor thickness (P=0.031) and clinical stage (P=0.006). The median overall survival for patients with high expression of NRAS isoform 3 was significantly shorter than that for patients with low expression of NRAS isofor...
Source: Melanoma Research - April 25, 2019 Category: Cancer & Oncology Tags: ORIGINAL ARTICLES: Translational research Source Type: research